Catalent to purchase Italy manufacturing facility from BMS
pharmafile | June 20, 2019 | News story | Manufacturing and Production, Sales and Marketing | BMS, Bristol-Myers Squibb, Cataletnt, pharma
Bristol-Myers Squibb has reached an agreement with Catalent for the latter to acquire its Anagni, Italy-based facility which specialises in the manufacturing and packaging of oral solid, biologics, and sterile products, it has emerged.
The facility has been a primary platform from which BMS launched a slew of its drugs, in particular in the treatment of cancer and cardiovascular disease. Catalent said that it hoped the purchase would provide its biologics customers with “access to an advanced sterile drug product fill/finish and packaging capacity in Europe to complement its existing sterile fill/finish capabilities in Belgium and its drug substance, analytical and fill/finish capabilities in North America.”
Catalent confirmed it would continue to manufacture BMS’ current portfolio at the site after the closing of the deal.
“We believe that the sale to Catalent will continue the vital role the Anagni facility plays for its workforce, the community and patients,” said Lou Schmukler, President, Global Product Development and Supply, Bristol-Myers Squibb. “This marks an important step in the ongoing evolution of our manufacturing network to support the company’s innovative product portfolio. Bristol-Myers Squibb has a long history in Italy, and we intend to maintain a continued strategic presence in Italy, which is critical for our ability to deliver transformational medicines to patients.”
Alessandro Maselli, Catalent’s President and Chief Operating Officer, commented, “The addition of the Anagni facility provides our European customers with great biologics and oral dose capabilities to accelerate their development programs and improve commercial supply.” He added, “Bristol-Myers Squibb has invested in the facility to create a centre of excellence for new product launches with a robust quality and delivery record, and an employee base who shares Catalent’s operational excellence and patient focus.”
The transaction is estimated to complete by the end of the year, subject to “regulatory approvals, the information and consultation procedure with the unions, and the satisfaction of certain other customary closing conditions”, the pair of companies said.
Matt Fellows
Related Content
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
Johnson & Johnson announces successful results from trial for myeloma treatment
Global healthcare company, Johnson & Johnson, announced that analysis of its Darzalex (daratumumab) therapy showed …
Bend Bioscience adds commercial spray drying facility to Georgia site
Bend Bioscience has announced the addition of a commercial-scale spray dryer and a Gerteis dry …
